-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F/LaXTOd/hC3DzzPjChiO59xZTA7eJNn6noX7xQ0QLtxDpBPV4ly/BfY57TII9fc 05e0cMqzH3t6oD46Mf944A== 0001246360-10-002891.txt : 20100804 0001246360-10-002891.hdr.sgml : 20100804 20100804155029 ACCESSION NUMBER: 0001246360-10-002891 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100802 FILED AS OF DATE: 20100804 DATE AS OF CHANGE: 20100804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mackin James P CENTRAL INDEX KEY: 0001408470 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-07707 FILM NUMBER: 10990971 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY MS LC310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTRONIC INC CENTRAL INDEX KEY: 0000064670 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 410793183 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 BUSINESS PHONE: 7635144000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY CITY: MINNEAPOLIS STATE: MN ZIP: 55432 4 1 form.xml PRIMARY DOCUMENT X0303 4 2010-08-02 false 0000064670 MEDTRONIC INC MDT 0001408470 Mackin James P 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 false true false false SVP & Pres CRDM Common Stock 769.884 I ESOP Common Stock 2010-08-02 4 A false 8900 0 A 102940.814 D Employee Stock Option (right to buy) 37.53 2010-08-02 4 A false 35492 0 A 2011-08-02 2020-08-02 Common Stock 35492 35492 D This balance increased by 522.399 due to exempt transactions such as dividend reinvestment and dividend equivalent credits. The restrictions on these restricted stock units shall lapse on the third anniversary of the grant date if the company's cumulative diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2013 equals or exceeds a 5% compound annual growth rate, as determined by the Compensation Committee. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Rhonda L. Ingalsbe, Attorney-in-fact 2010-08-04 -----END PRIVACY-ENHANCED MESSAGE-----